Technical feasibility and safety of a new, implantable reflux control system to prevent gastroesophageal reflux in patients with stents placed through the lower esophageal sphincter (with video)
Background
When an esophageal stent is placed through the lower esophageal sphincter (LES), gastroesophageal reflux symptoms may persist despite high-dose proton pump inhibitor therapy. A recently developed, short segment, uncovered nitinol stent with a tricuspid-like valve can be placed inside a previously placed esophageal stent.
Objective
To evaluate the technical feasibility and safety of a reflux control system (RCS) in distally placed esophageal stents.
Design
A prospective case series.
Setting
Two tertiary-care referral centers.
Patients
This study involved 10 patients who had an “open” stent placed through the LES and 1 patient with severe bile reflux after esophagojejunostomy.
Intervention
Placement of an RCS with fluoroscopic and (in selected cases) endoscopic guidance, from April to October 2010.
Main Outcome Measurements
Technical success of RCS placement and complications.
Results
Placement of an RCS was successful on the first attempt in all patients; complete expansion to the wall of the host stent was confirmed by fluoroscopy in all cases. In 3 patients, the host stent migrated in <1 month with the RCS still inside. In 8 patients, the RCS was in place for a median of 134 days (range 33-225 days). Three patients died because of malignant disease progression. Eight RCSs were removed endoscopically, together with the host stent without complications. RCS migration did not occur.
Limitations
Small number of patients, nonrandomized design, lack of pH measurements.
Conclusion
Placement of an RCS in a host stent is technically feasible and safe. An RCS can be considered in symptomatic patients with open esophageal stents to prevent gastroesophageal reflux.
Abbreviations: GEJ, gastroesophageal junction, ERCS, EndoFLUXX Reflux Control System, LES, lower esophageal sphincter, PPI, proton pump inhibitor, RCS, reflux control system, SEMS, self-expandable metal stent
To access this article, please choose from the options below
DISCLOSURE: P.D. Siersema serves as an advisor to Boston Scientific Corp, USA and receives research support from Astra Zeneca BV, The Netherlands, and Cook Medical Ltd, Ireland. No other financial relationships relevant to this publication were disclosed.
If you would like to chat with an author of this article, you may contact Dr Hirdes at M.M.C.Hirdes@umcutrecht.nl
PII: S0016-5107(11)02119-5
doi:10.1016/j.gie.2011.08.037
© 2012 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
